Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
US12383521B2 · kind B2 · utility
0Cited by
67References
21Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 7, 2022 |
| Grant date | Aug 12, 2025 |
| Priority date | — |
| Expiry date | Mar 15, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K40/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.